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Abstract
Companion diagnostics rely on genomic testing of molecular alterations to enable effective cancer treatment. Here we
report the clinical application and validationof theOncomineFocusAssay (OFA), an integrated, commercially available next-
generation sequencing (NGS) assay for the rapid and simultaneous detection of single nucleotide variants, short insertions
and deletions, copy number variations, and gene rearrangements in 52 cancer genes with therapeutic relevance. Two
independent patient cohorts were investigated to define the workflow, turnaround times, feasibility, and reliability of OFA
targeted sequencing in clinical application and using archival material. Cohort I consisted of 59 diagnostic clinical samples
from the daily routine submitted for molecular testing over a 4-month time period. Cohort II consisted of 39 archival
melanomasamples thatwere up to 15 years old. Librarieswereprepared from isolatednucleic acids and sequencedon the
Ion Torrent PGM sequencer. Sequencing datasets were analyzed using the Ion Reporter software. Genomic alterations
were identified and validated by orthogonal conventional assays including pyrosequencing and immunohistochemistry.
Sequencing results of both cohorts, including archival formalin-fixed, paraffin-embedded material stored up to 15 years,
wereconsistentwithpublishedvariant frequencies.Aconcordanceof 100%betweenestablishedassaysandOFA targeted
NGS was observed. The OFA workflow enabled a turnaround of 3½ days. Taken together, OFA was found to be a
convenient tool for fast, reliable, broadly applicableandcost-effective targetedNGSof tumorsamples in routinediagnostics.
Thus, OFA has strong potential to become an important asset for precision oncology.
Neoplasia (2017) 19, 196–206
Introduction
Next-generation sequencing (NGS) is an emerging technology for
molecular diagnostics. It enables the parallel identification of multiple
genomic variants even from small tissue samples [1,2]. Scalable and
cost-effective NGS solutions to reliably identify therapeutically
relevant genomic driver alterations of tumors are the prerequisite
for precision oncology. However, implementing multiplexed and
comprehensive NGS assays into the clinical routine is challenging
because data analysis and interpretation require specialty infrastruc-
ture and expertise [3]. In addition, most established routine tests
cannot assess somatic copy number variations (SCNVs) and/or gene
fusions, which presently guide treatment selection for several
common cancers [4]. To make precision medicine approaches
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available for all cancer patients, there is a need for fast, reliable, and
cost-effective NGS systems that can detect all classes of currently
clinically relevant genomic targets from routine formalin-fixed,par-
affin-embedded (FFPE) tissues [5–7]. To address these challenges,
targeted NGS solutions have been developed to identify recurrently
altered oncogenes as well as tumor suppressors, genes with frequent
high-level amplifications or deletions, and driving gene fusions in a
variety of cancers [8]. However, this emerging approach has so far not
been sufficiently evaluated on routine diagnostic FFPE material in
terms of feasibility, reliability, cost, and capacity [6,9,10].
The Oncomine Focus Assay (OFA, Thermo Fisher Scientific, San
Francisco, CA) is a targeted, multibiomarker NGS assay that enables
fast simultaneous detection of hundreds of variants across 52 genes
relevant to solid tumors [8,11]. These variants are treatable by
on-market oncology drugs approved by the U.S. Food and Drug
Administration as well as drugs that are part of the National
Comprehensive Cancer Network guidelines or are currently listed in
clinical trials [8,11]. The assay analyzes clinically relevant gene
alterations including single nucleotide variants, short insertions and
deletions, SCNVs, and gene fusions from DNA and RNA in a single
workflow. It enables the detection of tumor-specific genomic
alterations using low-input FFPE samples such as needle biopsies
and fine needle aspirates and is compatible with benchtop Ion
Torrent sequencers. The power of the OFA technology for
identification of genetic alterations is underlined by the present
application in the nationwide NCI–Molecular Analysis for Therapy
Choice Trial [12]. Here we evaluated the performance and
applicability of this novel targeted NGS assay for transfer into daily
diagnostic practice.
Materials and Methods
Study Cohorts and Patient Selection
This study was carried out in accordance with the guidelines of the
Cantonal Ethics Committee Basel (KEK-EKBBno. 326-12,
2016-01134, and 2016-01499). Cohort I consisted of 59 diagnostic
FFPE tissue samples from 51 consecutive patients that were analyzed
in the diagnostic routing during a 4-month time period (March-June
2016). All patients had a clinical indication for molecular testing and
were informed about the purpose of the molecular analysis by the
treating physician. The demographic and histopathological features of
these prospectively collected samples are listed in Table 1. Cohort II
consisted of 39 archival FFPE tissue samples from 39 patients with
cutaneous malignant melanoma. Tissue blocks were up to 15 years
old. Median follow-up was 19.5 months (range 0-62 months) for
cases with lymph node or distant metastasis and 27 months (range
12-144 months) for cases without metastases. Patients in this cohort
were characterized and described in a previous study (cohort 1 with
57 patients in Garg et al.). [13] Cases with insufficient material
remaining on the tissue block were excluded from molecular analysis
(n = 18). The clinicopathological features of cohort II are provided in
Table 2.
Genomic Profiling of Samples by Targeted NGS
All samples in this study were analyzed using the commercially
available OFA platform. The genes targeted in this panel are carefully
selected biomarkers derived from expertly curated cancer genomics
data [8]. The assay analyzes a maximum of six parallel samples per run
for DNA and RNA. It can be used on FFPE samples (10 ng DNA
and 10 ng DNase-treated RNA per reaction) and is compatible with
benchtop Ion Torrent sequencers (Ion Personal Genome Machine,
Ion Proton System, Ion S5 System, Thermo Fisher Scientific).
The percentage of tumor cells relative to other cells (e.g., stromal,
inflammatory, and preexisting epithelial cells) was estimated on one
hematoxylin and eosin (H&E) stained tumor section by a
Table 1. Demographic and Histopathological Features of the Prospective Clinical Samples (Cohort I)
Characteristic n = 51 %
Gender
Male 28 54.9
Female 23 45.1
Age
Median 67 –
Range 31-85 –
Tumor entities (n = 51)
Colorectal cancer 20 39.2
Non–small cell lung cancer 19 27.3
Thyroid cancer 3 5.9
Melanoma 2 3.9
Pancreatic cancer 2 3.9
Breast cancer 2 3.9
GIST 1 2.0
Nonmelanoma skin cancer 1 2.0
Erdheim Chester disease 1 2.0
Non–small cell lung cancer (n = 19)
Adenocarcinoma 15 78.9
Squamous cell carcinoma 1 5.3
Pleomorphic carcinoma 1 5.3
Combined 1 5.3
NOS 1 5.3
Primary tumor/metastasis
Primary tumor only 32 62.7
Metastasis only 13 25.5
Matched primary and metastasis 3 5.9
Two different primary tumors † 3 5.9
Nucleic acid analysis
DNA and RNA 39 76.5
DNA only 12 23.5
Tumor cell content
10%-30% 7 13.7
31%-70% 15 29.4
N70% 29 56.9
Combined small cell carcinoma with adenocarcinoma and sarcoma components.
† Two different, synchronous or metachronous primary tumors or different manifestations of the disease
(for Erdheim Chester disease case) were analyzed.
Table 2. Demographic and Histopathological Features of 39 Archival Cutaneous Melanoma
Samples (Cohort II)
Characteristic n = 39 %
Gender
Male 24 61.5
Female 15 38.5
Age
Median 70 –
Range 31-91 –
Melanoma types
Superficial spreading melanoma 24 61.5
Nodular melanoma 15 38.5
Metastases
Melanoma with metastases 12 30.8
Melanoma without metastases 27 69.2
Tumor cell content
10%-30% 9 23.1
31%-70% 7 17.9
N70% 23 59.0
The cohort consisted of cases with lymph node and/or distant metastases detected at the time of first
diagnosis or during a median follow-up of 19.5 months (range 0-62 months) and of cases with no evidence
of no lymph node and/or distant metastases at the time of first diagnosis or during a median follow-up of
27 months (range 12-144 months).
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board-certified molecular pathologist (K.D.M.), and an area with a
minimum tumor cell content of N20% was designated for the
analysis. FFPE tissue sections (4 μm) on positively coated slides were
deparaffinized by a standard procedure (2 × 15 minutes in xylol,
5 minutes in absolute EtOH). The defined tumor area was
transferred into an Eppendorf LoBind PCR tube (Eppendorf,
Hamburg, Germany). For the direct DNA extraction, the dissected
tissue was mixed with digestion buffer (50mM Tris–-HCl pH 8.5,
1 mM EDTA pH 8.0, 5% Tween 20, 6 mg/ml of proteinase K;
Qiagen, Hilden, Germany) followed by thermomixer incubation
(1 hour at 56°C and 5 minutes at 95°C). This crude extract was
directly processed or frozen at −20°C for long-term storage. RNA was
extracted from FFPE samples using the Recover All Total Nucleic
Acid Isolation kit by the “RNA Only” protocol as described by the
manufacturer (Ambion, Thermo Fisher Scientific). Nucleic acid
concentrations were measured by the Qubit dsDNA HS and the
Qubit RNA HS Assay kits, respectively, with the Qubit Fluorometer,
and RNA was reverse transcribed to cDNA using the SuperScript
VILO cDNA synthesis kit (all from Thermo Fisher Scientific).
Libraries were prepared using the Ion PGM Select Library kit and
were equalized to 100 pm concentration using the Ion PGM Select
Library Equalizer kit. Templation and enrichment were performed
using the Ion OneTouch Select Template Kit (all from Thermo
Fisher Scientific) on Ion OneTouch 2 and Ion OneTouch ES
instruments. The library was sequenced using the Ion PGM
sequencer (Thermo Fisher Scientific). The run was considered
successful and the sequencing quality adequate when the following
quality metrics were met: 1) mapped reads ≥300,000; 2) average base
coverage depth ≥1000; 3) amplicons having at least 500 reads: ≥90%;
4) no strand bias: ≥90%; 5) amplicons read end-to-end: ≥85%. Five
thousand mapped reads were set as the limit for a single RNA library.
Primary analysis was performed by Torrent Server™ (v 5.0) and
further by Ion Reporter™ Server hosting informatic tools (Ion
Reporter™ Software v5.0) for variant analysis, filtering, and
annotations. Automatic workflow (Oncomine Focus v2.0, DNA
and fusions/DNA/fusions, Single Sample) with preconfigured
parameter settings (Oncomine Variants 5% CI SCNV ploidy ≥
gain of 2 over normal) was utilized.
The performance of the OFA panel was ascertained using a highly
multiplexed test panel, the AcroMetrix Oncology Hotspot Control
(Thermo Fisher Scientific) targeting various mutations in 25 of the
genes represented in the OFA panel (AKT1, ALK, BRAF, CTNNB1,
EGFR, ERBB2, ERBB4, FGFR2, FGFR3, GNA11, GNAQ, HRAS,
IDH1, IDH2, JAK2, JAK3, KIT, KRAS, MAP2K1, MET, NRAS,
PDGFRA, PIK3CA, RET, SMO), with a frequency near the limit of
detection (5%-35%). The performance of the OFA RNA part was
ascertained using the Lung Panel (ALK-RET-ROS1) FFPE RNA
Reference Standard (Horizon Discovery, Cambridge, UK).
Confirmation of Genetic Alterations by Alternative Methods
A random subset of samples of the two cohorts analyzed by the
OFA was selected for additional validation by alternative methods.
For validation of common hotspot mutations, pyrosequencing was
performed using the PyroMark Q24 system (Qiagen, Hilden,
Germany) and the following commercially available kits according
to the manufacturer's instructions: therascreen BRAF Pyro Kit (BRAF
codons 600 and 464-469), therascreen EGFR Pyro Kit (EGFR
codons 719, 768, 790, 858-861, exon 9 deletions), therascreen KRAS
Pyro Kit (KRAS codons 12,13, and 61), therascreen NRAS Pyro Kit
(NRAS codons 12,13, and 61), and therascreen RAS Extension Pyro
Kit (KRAS codons 59, 61, 117, 146; NRAS codons 59, 61, 117,
146). Four samples of cohort I [n = 4, the first three cases of non–
small cell lung cancer (NSCLC) and the first case of colorectal cancer
(CRC) during the 4-month time period] were analyzed by the Ion
AmpliSeqColon and Lung Cancer Research Panel v2 (CLPv2,
Thermo Fisher Scientific), an alternative targeted NGS
panel (Supplementary Table S1). For cases with ALK1, ROS1, or
MET inter- or intragenic fusions detected in the RNA part of the
assay (n = 7) and for cases with SCNVs/amplifications affecting the
genes CCND1 (Cyclin D1; n = 1) or MYC (n = 2), results were
confirmed by immunohistochemistry (IHC) (Table 3; Supplemen-
tary Table S2). For the two breast cancer cases analyzed, HER2 silver
in situ hybridization (SISH; Ventana/Roche Diagnostics, Mannheim,
Germany) and HER2 IHC were performed according to the
manufacturer's instructions (Supplementary Table S2). Our labora-
tory, including the above mentioned standard assays (IHC, SISH,
pyrosequencing), is certified by the Swiss Accreditation Service (STS
0599) according to the ISO/IEC 17025 und ISO 15189.
Results
First, we evaluated the performance of the OFA in the
prospective clinical setting of 59 diagnostic FFPE tissue samples from
51 consecutive patients of cohort I that were routinely submitted to
our molecular pathology service during a 4-month time period
(March-June 2016). The main entities that were analyzed during this
time included CRC (20 patients, 39.2%) and NSCLC (19 patients,
37.3%). For the vast majority of patients, the treating physician was
interested in tumor-specific genomic alterations with predictive value.
In six cases, the treating physician requested information on clonal
relationships between different primary tumors of the patient or
between a primary tumor and metastases. Therefore, two different
tissues were analyzed for five patients (two primary tumors or primary
tumor and corresponding metastasis for patient nos. 16, 20, 25, 44,
and 51; Supplementary Table S3), and four different tissues were
analyzed for one patient (three different morphologic components of
a combined small cell/non –small cell lung carcinoma and one
corresponding metastasis in the small bowel, patient no. 8;
Supplementary Table S3). All samples underwent successful targeted
sequencing of the 52 OFA genes (Figure 1A). The OFA workflow
enabled a fast turnaround of 3½ days (Figure 1B). Importantly, the
nested design thereby enables simultaneous DNA and RNA analysis,
with RNA extraction and analysis requiring an additional working
time of approximately 2 hours.
In the OFA DNA analysis, 51 (86.4%) of the 59 prospectively
collected samples from routine diagnostics showed at least 1
alteration, whereas only 8 samples (13.6%) did not show any
alterations with this panel (Supplementary Table S3). Of the 51
samples with alterations detected by OFA, 34 (66.7%) had just 1
alteration, 11 (21.6%) had 2 alterations, 5 (9.8%) had 3 different
alterations, and 1 sample (no. 19; 2%) had 4 different alterations. The
most frequently mutated genes in these routine diagnostic cases across
all tumor types included KRAS (20 patients, 39.2%), BRAF (7
patients, 13.7%), PIK3CA (5 patients, 9.8%), MET (4 patients,
7.8%), EGFR (3 patients, 5.9%), NRAS (3 patients, 5.9%), and
CTNNB1 (3 patients, 5.9%). Analysis of copy number data revealed
the most frequent copy number gains in MYC (4 patients, 7.8%),
EGFR (2 patients, 3.9%), MET (2 patients, 3.9%), and FGFR1 (2
patients, 3.9%). One of the two melanomas included in this routine
198 Targeted NGS for Routine Molecular Profiling Paasinen-Sohns et al. Neoplasia Vol. 19, No. 3, 2017
diagnostics cohort was found to have amplifications in the region of
the BRAF (chromosome 7q34, copy number 18.25) and CDK4
(chromosome 12q14.1, copy number 48.65) gene (no. 39, 2%).
Most copy number gains co-occurred with other relevant hotspot
mutations, and only three patients (nos. 39, 45, 50; 5.9%) revealed
isolated amplifications and no additional hotspot mutations.
For the two breast cancer cases included in this study (no. 11, 13),
HER2 IHC showed a strongmembranous positivity (score 3+) without
evidence of ERBB2 (HER2) amplification by SISH. Molecular testing
was performed due to these inconsistent results. In both cases, the OFA
showed neither ERBB2 amplification nor ERBB2 mutation. Thus, the
OFA supports the in situ hybridization results, considered the gold
standard for analysis of HER2 in breast cancer.
In all five patients with two different samples analyzed (nos. 16, 20,
25, 44, 51; Supplementary Table S3), both samples (two primary
tumors or one primary and one metastasis) showed exactly the same
alterations. In one single patient with a combined small-cell lung
carcinoma with adenocarcinoma and sarcoma components (no. 8),
four different samples were analyzed. In this case, an activating EGFR
mutation in exon 21 (p. L858R) was detected both in the
adenocarcinoma and in the sarcoma components of the primary
tumor as well as in a metastasis with sarcomatous differentiation. The
sarcomatous primary tumor component and the sarcomatous
metastasis additionally showed FGFR1 and MYC amplifications.
No alterations were detected in the small cell component of the
primary tumor by OFA.
Table 3. Validation of the OFA Results by Orthogonal Testing (Cohort I)
Patient Diagnosis OFA Result Validation Method
1 NSCLC (squamous) BRAF p. G469V
FGFR1 amplification
Pyrosequencing, CLPv2
–
2 NSCLC (adeno) KRAS p. G12C
KRAS p. A59G CLPv2
3 CRC KRAS p. G13C
PIK3CA p. H1047R CLPv2
4 Melanoma NRAS p. A146T Pyrosequencing
5 NSCLC (pleo) KRAS p. G12A CLPv2
8 NSCLC (adeno), primary
NSCLC (sarcoma), primary
NSCLC (sarcoma), metastasis
SCLC, primary
EGFR p. L858R
EGFR p. L858R
FGFR1 amplification
MYC amplification
EGFR p. L858R,
FGFR1 amplification,
MYC amplification
–
Pyrosequencing
Pyrosequencing
–
–
Pyrosequencing
–
–
Pyrosequencing
10 NSCLC (adeno) – Pyrosequencing †
11 Breast cancer PIK3CA p. N345K HER2 IHC, HER2 SISH
13 Breast cancer PIK3CA p. E545K HER2 IHC, HER2 SISH
17 NSCLC (adeno) BRAF p. V600E Pyrosequencing
19 NSCLC (adeno) KRAS p. G12D
EGFR amplification
EGFRvIII
MET exon 14 mutation
–
–
–
MET IHC
23 CRC KRAS p. Q61K
CCND1 amplification
MYC amplification
–
CCND1 IHC
MYC IHC
25 NSCLC (adeno) 1
NSCLC (adeno) 2
CD74 – ROS1 fusion
CD74 – ROS1 fusion
ROS1 IHC
ROS1 IHC
27 CRC BRAF p. V600E
MYC amplification
–
MYC IHC
29 CRC PIK3CA p. R93Q
MAP2K1 (MEK) p. K57T
MET exon 14 mutation
–
–
MET IHC
30 Pancreatic cancer KRAS p. G12D
MET exon 14 mutation
–
MET IHC
32 NSCLC (adeno) EML4 – ALK fusion ALK IHC
35 CRC KRAS p. A146T Pyrosequencing
39 Melanoma BRAF amplification
CDK4 amplification
–
CDK4 IHC
40 NSCLC (adeno) CD74 – ROS1 fusion ROS1 IHC
43 Thyroid carcinoma (anaplastic) NRAS p. Q61K
MET exon 14 mutation
–
MET IHC
44 Thyroid carcinoma (papillary), primary
Thyroid carcinoma (papillary), metastasis
BRAF p. V600E
BRAF p. V600E
Pyrosequencing
Pyrosequencing
45 NSCLC (adeno) EGFR amplification
MET amplification
–
MET IHC
48 CRC KRAS p. G12V Pyrosequencing
50 NSCLC (NOS) MET amplification MET IHC
51 Erdheim Chester disease 1
Erdheim Chester disease 2
BRAF p. V600E
BRAF p. V600E
Pyrosequencing
Pyrosequencing
Abbreviations: NSCLC, non–small cell lung cancer; NSCLC (adeno), non–small cell lung cancer, adenocarcinoma; NSCLC (squamous), non–small cell lung cancer, squamous cell carcinoma; NSCLC
(pleo), non–small cell lung cancer, pleomorphic carcinoma; NSCLC (NOS), non–small cell lung cancer, not otherwise specified.
CLPv2 detected an additional TP53 mutation.
† No EGFR or KRAS mutation detected by pyrosequencing.
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Figure 1. Molecular profiling with the OFA, a targeted multibiomarker NGS assay. (A) The OFA is a targeted NGS panel that includes 52
solid tumor genes associated with current oncology drugs and published evidence. It enables sequencing of 35 hotspot genes, 19 genes
associated with copy number gain, and 23 fusion genes, all in a single workflow using the Ion PGM system. Genes printed in bold were
detected in cases of the two cohorts studied here. (B) Workflow and turnaround time for molecular profiling of clinical FFPE samples
using targeted NGS with the OFA. (C) Design of this study. The OFA was tested and validated on two different cohorts. Cohort I (left)
consisted of 59 routine FFPE samples from 51 patients with various solid tumors that were routinely submitted to the molecular
pathology service. Half of these samples were randomly selected for orthogonal validation by alternative tests. In addition, validation was
performed by comparing the OFA results with expectedmutation frequencies from the literature. Cohort II (right) was an archival cohort of
39 FFPE melanoma samples from 39 patients. Mutation frequencies were retrieved from the literature, and the samples of cohort II were
analyzed by the OFA retrospectively. The OFA results of the melanomas in cohort II were consistent with the data that can be expected
from large published cohorts of cutaneous melanomas.
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In the OFA RNA analysis, a total of eight driver fusions were
identified in MET (four patients, 7.8%), ROS1 (two patients, 3.9%),
ALK (one patient, 2%), and EGFR (EGFRvIII, one patient, 2%).
The inter- or intragenic MET, ROS1, and ALK fusions in seven of
these patients were confirmed by IHC demonstrating protein
overexpression of MET, ROS1, and ALK, respectively (Figure 2,
Table 3). All four patients with MET mutations detected in the OFA
RNA panel showed a fusion of MET exon 13 with exon 15 (so-called
MET “exon 14 skipping” mutations). This was a relatively frequent
event in our routine diagnostic cohort and was detected in various
unexpected entities (one adenocarcinoma of the lung, one CRC, one
pancreatic cancer, and one anaplastic thyroid carcinoma; Figure 2).
The MET exon 14 skipping mutations were not associated with
MET genomic amplifications [14]. The intragenic MET mutations
Figure 2. Validation of gene fusions and SCNVs detected in routine FFPE samples. (A) EML4-ALK intrachromosomal fusion found in
sample no. 32 (NSCLC, adenocarcinoma, H&E left). Confirmation of ALK overexpression due to this EML4-ALK gene fusion by IHC (right).
(B) CD74-ROS1 fusion found in sample no. 25 (NSCLC, adenocarcinoma, H&E left). Confirmation of ROS1 overexpression due to this gene
fusion between CD74 (Exon 6) and ROS1 (Exon 34) by IHC (right). (C) Intragenic MET fusion (Exon 13-Exon 15; MET “exon 14 skipping”)
found in sample no. 29 (lung metastasis of CRC, H&E left). Confirmation of membranous MET overexpression due to this MET exon 14
mutation by IHC (right). (D) MYC amplification found in sample no. 27 (CRC, H&E left). The gene region 8q24.21 on chromosome 8 had a
copy number of 25. Confirmation of MYC amplification by IHC (right).
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were not isolated events but co-occurred with hotspot mutations of
KRAS, NRAS, PIK3CA, or MAP2K1 (nos. 19, 29, 30, 43 in Table 3
and Supplementary Table S3). Similarly, the EGFRvIII intragenic
mutation (EGFR variant III) co-occurred in an NSCLC (adenocar-
cinoma) with a classic driver mutation in the KRAS gene (p. G12D),
an EGFR amplification, and a MET exon 14 mutation (no. 19 in
Table 3 and Supplementary Table S3) [15].
Half of the above patients (n = 26) were picked at random for
orthogonal validation of the alterations identified by OFA using a
variety of other established analysis techniques (Table 3). Orthogonal
testing included pyrosequencing and an alternate NGS assay (CLPv2)
to confirm the presence or the absence of selected hotspot mutations.
IHC and for some samples also SISH were used to validate the
predicted copy number gains or gene fusions observed by OFA
(Figure 2, Table 3). Overall, a concordance rate of 100% between the
results of the established assays and the novel targeted NGS approach
with OFA was observed. In one case of Erdheim Chester disease (no.
51), two different archival samples obtained at two different time
points were retrospectively analyzed by OFA to confirm a BRAF p.
V600E mutation previously detected by pyrosequencing. Indeed,
OFA confirmed this result. In patient nos. 2 and 3 of cohort I, an
additional TP53 mutation was detected by the CLPv2 (p. M246I in
no. 2, p. R267W in no. 3). However, this is not considered as a
discrepancy between the two assays because the TP53 gene is not a
therapeutically relevant target and, as such, is not represented in the
OFA panel.
Comparison of the OFA results with the expected variant
frequencies from the literature showed consistent results. Of the 20
CRC patients, 11 (55%) harbored a KRAS mutation and 3 (15%) a
BRAF mutation. Of the 19 NSCLC patients, 6 (31.6%) had a KRAS
mutation [1 of these 6 patients (no. 2) had two different KRAS
mutations in codons 12 and 59; Supplementary Table S3], 2 (10.5%)
an EGFR mutation, 2 (10.5%) a ROS1 rearrangement, and 1 (5.3%)
an ALK rearrangement. This means that, for most known mutations,
the OFA detection rate was in the range or above expected variant
frequencies (Figure 3) [16–18]. The OFA found additional actionable
alterations as a result of the broader target range (ability of OFA to
detect SCNVs and driver gene fusions that cannot be detected by
other commercial NGS assays) compared with traditional methods.
In some cases, major driver mutations coexisted with other relevant
variants, as in the CRC case nos. 3, 6, and 14 which showed KRAS
mutations (p. G13C, p. G12D, p. G13D) as well as a mutation in
PIK3CA (p. H1047R). PIK3CA mutations were not detected as an
isolated event in our cohort [19].
Next, we applied the OFA to an independent, well-characterized
cohort of 39 archival cutaneous malignant melanoma samples [13].
For these cases, DNA was isolated from archival FFPE blocks of
tumor samples that were up to 15 years old. All samples underwent
successful targeted sequencing of the 41 genes included in the OFA
DNA panel. Eight samples (20.5%) showed no relevant genomic
alteration detectable in the OFA DNA panel, 25 samples (64.1%)
had 1 alteration, 4 samples (10.3%) had 2 alterations, 2 samples
(5.1%) had 3 alterations, and 1 sample (2.6%) had 4 alterations. As
expected from large cohort studies, the most frequently mutated
genes were BRAF (14 samples, 35.9%) and NRAS (14 samples,
35.9%) (Figure 3, Supplementary Table S4) [20,21]. Amplifications
were rare events and were found in the regions of the CCND1,
CDK4, KIT, KRAS, and PDGFRA genes (Figure 3, Supplementary
Table S4) [20]. Altogether, amplifications were detected in 4 of the
39 patients (10.3% of patients). In two of these patients (no. 2, 24),
copy number gains co-occurred with relevant driver hotspot
mutations of the NRAS gene. Five melanoma samples were randomly
selected for further validation by pyrosequencing which confirmed
the OFA results.
Kinase fusions that can be detected in the OFA RNA panel
occur in a mutually exclusive pattern in cutaneous melanomas and are
not detected in melanomas with the classic BRAF or NRAS driver
mutations [21,22]. Therefore, RNA analysis was performed only in
the 10 melanoma samples without a detectable driver mutation in the
OFA DNA panel (“wild-type subtype”) (Supplementary Table S4).
Seven cases did not show any relevant alteration in the OFA RNA
panel. One case (2.6% of all patients) showed an ALK rearrangement
leading to a fusion between the TPM3 gene (exon 7) on chromosome
1q21 and the ALK gene (exon 20) on chromosome 2p23. Because of
this genomic rearrangement, TPM3 exon 7 is fused in-frame with
ALK exon 20, preserving the transforming tyrosine kinase domain of
ALK. The expression of this chimeric transcript was confirmed by
IHC showing a strong cytoplasmic ALK positivity of the archival
melanoma (no. 5, Figure 4, Supplementary Table S4). For two cases
(nos. 17, 21), it was not possible to isolate RNA because of
insufficient material remaining in the tissue block.
Discussion
Molecular profiling of cancer has become essential to predict
therapeutic response to targeted therapies. NGS has enabled
genomewide personalized oncology efforts for actionable variant
identification and prioritization. Here, we conducted a comprehen-
sive analysis and validation of a novel amplicon-based NGS solution
for identification of relevant somatic alterations in solid tumors. First,
we characterized the workflow, turnaround times, feasibility, and
reliability in the analysis of routine clinical tissue samples. OFA
performance was assessed using independent methods to confirm the
detected alterations. Second, we tested the retrospective analysis of
archival FFPE tissue samples in an independent cohort of
well-characterized malignant melanoma cases. In both settings, the
OFA was found to be a convenient tool for fast, reliable, easy-to-use,
broadly applicable, and cost-effective targeted NGS analysis.
Multibiomarker NGS assays from numerous commercial and
academic providers are rapidly reaching clinical application. Lower
cost and wider availability of NGS now raise the debate over the merit
of routine tumor genomic analysis. Although some genetic lesions are
targeted by a new generation of cancer therapies and certain treatment
regimens are coupled to single gene assays, we still do not know if the
vast majority of information on other genomic alterations is worth the
added cost and if assignment of patients to off-label treatment with a targeted
agent might carry potentially serious side effects. We tested the OFA NGS
solution which focuses on a carefully selected panel of genomic alterations
with therapeutic relevance in comparison to other amplicon-based assays on
the market (Supplementary Table S1) [8]. The OFA thereby promises to
avoid time consuming and costly analyses of molecular changes without
knownpredictive value. As definedmolecular alterations are currently used to
drive treatment selection, the OFA appears to be a highly suitable tool for
molecular routine diagnostics [23–26]. Further, the high sensitivity of the
OFA allows to study cases with intratumoral genetic heterogeneity and
potential low-level alterations, as is the case for acquiredmutations conferring
resistance to tyrosine kinase inhibitor therapies [27,28]. In the present study,
several actionable somatic alterations were detected in NSCLC samples with
tumor purity as low as 10% to 20%.
202 Targeted NGS for Routine Molecular Profiling Paasinen-Sohns et al. Neoplasia Vol. 19, No. 3, 2017
Before NGS technologies can be applied in the daily routine,
systematic studies are needed to ensure consistent and reliable assay
performance. Comparison with current conventional tests with
respect to turnaround time, sensitivity, specificity, mutation detection
limits, costs, and feasibility is required. In the present study, we
identify a 100% concordance between the OFA results and
alternative methods including pyrosequencing and an alternate
NGS assay (CLPv2) in two independent patient cohorts. Of the 35
hotspot genes included in the OFA panel, mutations in 10 different
genes were detected in the 2 cohorts of this study (Figure 1A, printed
in bold). Alterations were identified in 9/19 genes associated with
copy number gains and 4/23 fusion genes (Figure 1A, printed in bold).
Overall, genomic alterations including hotspot mutations, amplifica-
tions, and gene fusions in 18 (34.6%) of the 52 therapy relevant genes
covered by the OFA were detected. Of these 18 alterations, we
validated 11 (61.1%, 21.2% of all 52 cancer genes included in the
OFA) with alternative methods (BRAF, EGFR, KRAS, NRAS
hotspot mutations, CCND1, CDK4, MET, MYC amplifications,
ALK, MET, ROS1 driver gene fusions). These alterations represent
the most common changes observed in CRC, NSCLC, and
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n=4
KRAS mutation
BRAF mutation
PIK3CA mutation
MET exon 14 mutation
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n=3
KRAS mutation
EGFR mutation
BRAF mutation
CTNNB1 mutation
MET exon 14 mutation
EGFR amplification
MET amplification
FGFR1 amplification
ROS1 fusion
ALK fusion
no alteration
14
14
6
5
n=8
NRAS mutation
BRAF mutation
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other mutations
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A
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C
Alterations in colorectal cancer 
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Alterations in melanoma 
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mutation Exon n
p.G12A 2 1
p.G12C 2 2*
p.G12D 2 1
p.G12S 2 1
p.G12V 2 1
p.A59G 3 1
KRAS 
mutation Exon n
p.G12D 2 3
p.G12V 2 2
p.G13C 2 1
p.G13D 2 3
p.Q61K 3 1
p.A146T 4 1
NRAS 
mutation Exon n
p.G12C 2 1
p.Q61R 3 6
p.Q61K 3 5
p.Q61L 3 1
p.Q61H 3 1
BRAF 
mutation Exon n
p.V600E 15 11
p.V600R 15 1
p.V600G 15 1
p.V600K 15 1
n= number of cases 
*One case with two KRAS mutations
Figure 3. Genomic aberrations in different tumor types. (A) Actionable variants in 20 CRC patients (n = number of patients) (left).
Distribution of KRASmutations that were detected in 11 (55%) CRC patients (right). (B) Actionable variants detected in 19 NSCLC patients
(left). Distribution of KRAS mutations that were detected in six (31.6%) NSCLC patients (right). One NSCLC patient harbored two different
KRAS mutations (p. G12C and p. A59G). (C) Actionable variants detected in 39 melanoma patients (left). Distribution of BRAF (right, top
panel) and NRAS (right, bottom panel) mutations identified in 14 (35.9%) melanomas.
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malignant melanoma [16–18,20]. KRAS/NRAS mutations occur in
approximately 50% of CRCs, 32% of NSCLCs (adenocarcinoma),
and 28% of cutaneous melanomas. BRAF mutations are found in
10% of CRCs, 7% of NSCLCs (adenocarcinoma), and 52% of
cutaneous melanomas. EGFR mutations, and ALK and ROS1 gene
fusions are identified in 11.3%, 1.3%, and 1.7% of NSCLCs
(adenocarcinoma), respectively [16–18,20]. Taken together, this
study validated the OFA for detection of approximately 60% of
genomic alterations occurring in CRCs, 53% of those occurring in
NSCLCs (adenocarcinoma), and 70% of the alterations commonly
found in cutaneous melanomas. The conformity of the data with
published variant frequencies further supports that this novel targeted
NGS approach is a reliable and reproducible method for detection of
therapeutically relevant genomic alterations in these entities.
Application of the OFA was also successfully tested in samples of
breast, gastrointestinal, and thyroid cancer but needs to be indepen-
dently confirmed due to the limited number of cases under study.
We illustrate that the OFA can reliably detect single genomic
events in rare tumor entities, as illustrated by the detection of a rare
TPM3-ALK translocation in one archival melanoma sample that was
previously classified as an ulcerated cutaneous melanoma (nodular
type). The patient was initially diagnosed with stage pT4b disease and
skin metastases but was alive without evidence for disease recurrence 9
years after the initial diagnosis. ALK fusions are typically found in
Spitz tumors of the skin, including Spitz naevi, atypical Spitz tumors,
and spitzoid melanomas [21,22,29,30]. In these cases, ALK fusions
are associated with a good prognosis and might be targetable with
tyrosine kinase inhibitors such as crizotinib [21,22,29,30]. The OFA
result therefore provided a retrospective explanation for the unusual
clinical course of this melanoma patient. Further, the OFA analysis
also offered valuable information for a potential systemic therapy in
the case of future recurrence and prompted a reclassification of the
tumor based on molecular changes. This case illustrates the
importance of a correlation between genomic aberrations and
histopathological evaluation. For example, a patient with an ALK
fusion–positive spitzoid melanoma can be expected to have a
favorable prognosis, but a tumor with the same morphological
characteristics and a BRAF mutation should raise the suspicion of an
aggressive clinical course and should result in timely clinical
intervention [20,21]. In these situations, integration of clinical,
histopathological, and molecular data, ideally in the context of an
interdisciplinary molecular tumor board, plays an essential role for
diagnosis, prognostic assessment, and targeted treatment of tumors [31].
MET intragenic fusions with skipping of exon 14 were relatively
frequently detected by the OFA in our routine diagnostic cohort
(cohort I) [14,32–36]. All four cases with MET exon 14 mutations
were validated by IHC in this study and showed a strong and
homogenous membranous MET overexpression in the tumor cells.
The high frequency of these MET fusions could be due to a bias by
the small number of cases included in this study and therefore
requires further validation in larger cohorts. MET mutations were
also unexpectedly detected in tumor entities such as pancreatic and
thyroid cancer that are not routinely submitted for molecular analysis
by NGS [33,34,36]. Thus, the high number of MET intragenic
fusions reported here could also be due to the fact that molecular
diagnostic approaches are not routinely applied on these rare and fatal
malignancies with limited or no conventional therapeutic options. In
addition, splicing of the MET gene is complex, variable, and poorly
understood [14,37]. Thus, we cannot exclude that the OFA might
detect splicing variants of unknown significance. As it is presently
unknown whether METmutations in these tumor entities are also
responsive to MET inhibition, further studies are needed to
investigate the therapeutic relevance of these findings.
The retrospective analysis of archival material and tissue bank
samples is of central importance for patients with relapsed disease.
However, the analysis of FFPE tissue can be challenging due to
fixation-induced crosslinking and fragmentation of nucleic acids.
[38,39] Here, we successfully applied the OFA for analysis of archival
FFPE tissue blocks of malignant melanoma aged up to 15 years. The
frequency of detected genomic alterations in the 41 genes included in
the OFA DNA panel was consistent with published data. This
indicates that the OFA is a reliable and reproducible method for
analysis of archival FFPE material. We successfully performed RNA
Figure 4. Detection and validation of an ALK translocation in one
archival melanoma. (A) Relatively symmetrical, exophytic, predom-
inantly intradermal melanocytic tumor with focal epidermal
hyperplasia from the right earlobe of a 30-year-old man. (B)
Plexiform growth pattern and intersecting fascicles of fusiform
melanocytes. Proliferation of spindle and epithelioid melanocytes.
(C) The neoplastic melanocytes are positive for ALK in IHC, with
strong staining of the cytoplasm. The ALK expression confirms the
presence of a TPM3-ALK fusion in this melanoma which was
retrospectively reclassified as a melanoma with spitzoid features.
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extraction and analysis in 8 out of 10 cases where no relevant driver
mutations were detected in the DNA panel. Importantly, RNA
quality from FFPE material has been shown to be less affected than
DNA by fixation-induced crosslinking and fragmentation, allowing
the application of the OFA RNA panel for identification of relevant
driver gene fusions in the retrospective setting [38,39].
Eight samples of the routine diagnostics cohort (13.6%, cohort I)
and seven melanoma samples (17.9%, cohort II) did not show any
detectable alterations with the OFA. For these cases, we cannot
exclude the possibility that they are “false negative” and may show
genomic alterations with other NGS assays analyzing targets that are
not covered by the OFA and thus cannot be detected with this assay.
However, the vast majority of additional genetic alterations likely
have no predictive value at the present time. The issue of
“false-negative” results is exemplified by the four samples that
underwent additional analysis by the CLPv2 assay. Additional TP53
mutations were identified in two of these four samples. However, we
do not consider these findings as a relevant discrepancy or
disadvantage of the OFA because the TP53 gene is not a
therapy-relevant target and as such is not included in the OFA panel.
In the retrospective cohort, 18 cases were excluded because
insufficient material remained on the tissue blocks for analysis. This
high proportion is explained by the prior use of material in research
studies and is likely not representative of the exclusion rate in a
standard setting. This is underlined by successful retrieval of tissue
material in all of the 59 cases of the routine diagnostics cohort.
Nevertheless, the careful disposition of diagnostic material is highly
important for personalized molecular diagnostics. In the present
study, several samples with a low tumor cell content of only 10% to
30% were successfully analyzed using both the DNA and RNA panel,
underlining previous data on the feasibility of targeted, high-depth
NGS in low-input samples [10].
Turnaround time and costs are key issues for the transfer of NGS
to routine molecular diagnostics. The direct material costs for analysis
of one sample by the OFA is approximately $450 in our laboratory
including chemicals. Depending on the type of sample analyzed, the
cost–-benefit ratio appears to be generally more favorable than that of
conventional assays. As an example, the direct material costs for
comprehensive testing of one lung cancer sample for EGFR, BRAF,
KRAS, and NRAS mutations using pyrosequencing and fluorescence
in situ hybridization for ALK and ROS presently amount to
approximately $1000 in our laboratory. Another benefit of the
OFA is a fast turnaround time which saves resources and associated
costs. The required time from specimen acquisition to clinical
reporting is only 3½ days, which is faster than any other NGS assay
currently available on the market.
In conclusion, our study validates the OFA in clinical routine
diagnostics and proves the reliability of this targeted NGS system for
identification of actionable genetic alterations in FFPE tumor
samples. Compared with conventional gene-specific assays, the
OFA showed significant advantages in terms of sensitivity, costs,
turnaround time, and a broader range of detectable relevant
alterations. We are confident that the OFA has strong potential for
routine clinical tumor testing and will promote precision oncology
efforts at an unforeseeable pace.
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